🇺🇸 FDA
Pipeline program

DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

MK-7902-009

Phase 2 small_molecule active

Quick answer

DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib for Recurrent or metastatic squamous cell carcinoma of the head and neck is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Recurrent or metastatic squamous cell carcinoma of the head and neck
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials